Lewis, K., Blombery, P., Sungala, N. P., Giri, P., Marconi, T., Cochrane, T., Francis, R., Lee, S., Ma, C. K. K., Vanguru, V., Manos, K., Keane, C., Hunter, S., Burgess, M., Kannan, S., Carlson, J., Walia, M., Butcher, B., Cheah, C. (2025). Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial. Blood. https://doi.org/10.1182/blood-2025-1016